These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36263669)

  • 1. COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.
    Cheung KS; Mok CH; Mao X; Zhang R; Hung IF; Seto WK; Yuen MF
    Clin Mol Hepatol; 2022 Oct; 28(4):890-911. PubMed ID: 36263669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of COVID-19 vaccines in chronic liver disease patients and liver transplant recipients: A systematic review and meta-analysis.
    Luo D; Chen X; Du J; Mei B; Wang A; Kuang F; Fang C; Gan Y; Peng F; Yang X; Dahmen U; Li B; Song S
    Liver Int; 2023 Jan; 43(1):34-48. PubMed ID: 35986903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    Thuluvath PJ; Robarts P; Chauhan M
    J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study.
    Ai J; Wang J; Liu D; Xiang H; Guo Y; Lv J; Zhang Q; Li J; Zhang X; Li Q; Liang J; Guo X; Feng Y; Liu L; Zhang X; Qin W; Wang X; Rao W; Zhang Q; Tian Q; Zhang Y; Xie F; Jiang S; Yan Y; Qiu Y; Wu H; Hou Z; Zhang N; Zhang A; Ji J; Yang J; Huang J; Zhao Z; Gu Y; Bian L; Zhang Z; Zou S; Ji H; Ge G; Du X; Hou A; Zhu Y; Cong Q; Xu J; Zu H; Wang Y; Yan Z; Yan X; BianBa Y; Ci Q; Zhang L; Yang S; Gao X; Zhong L; He S; Liu C; Huang Y; Liu Y; Xu D; Zhu Q; Xu X; Lv M; Zhang W; Qi X
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1516-1524.e2. PubMed ID: 34942370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases.
    Chauhan M; Nzeako I; Li F; Thuluvath PJ
    Ann Hepatol; 2022; 27(4):100702. PubMed ID: 35338012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroconversion and safety of Covid-19 vaccines in pa-tients with chronic liver disease and liver transplant: A systematic review.
    Elzouki AY; Elshafei MN; Aziz A; Elzouki I; Waheed MA; Farooqui K; Azad AM; Habas E; Danjuma MI
    Qatar Med J; 2023; 2023(3):21. PubMed ID: 38089670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines.
    Duan B; Zhang G; Wang W; Yin J; Liu M; Zhang J; Chen D; Ouyang Y; Li G
    Front Immunol; 2022; 13():954177. PubMed ID: 36189318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    Wang J; Hou Z; Liu J; Gu Y; Wu Y; Chen Z; Ji J; Diao S; Qiu Y; Zou S; Zhang A; Zhang N; Wang F; Li X; Wang Y; Liu X; Lv C; Chen S; Liu D; Ji X; Liu C; Ren T; Sun J; Zhao Z; Wu F; Li F; Wang R; Yan Y; Zhang S; Ge G; Shao J; Yang S; Liu C; Huang Y; Xu D; Li X; Ai J; He Q; Zheng MH; Zhang L; Xie Q; Rockey DC; Fallowfield JA; Zhang W; Qi X
    J Hepatol; 2021 Aug; 75(2):439-441. PubMed ID: 33905793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing immunogenicity and safety of SARS-CoV-2 vaccine in liver transplantation recipients: a systematic review and meta-analysis.
    Luo X; Lessomo FYN; Yu Z; Xie Y
    Front Immunol; 2023; 14():1145081. PubMed ID: 37731498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients.
    Kulkarni AV; Jaggaiahgari S; Iyengar S; Simhadri V; Gujjarlapudi D; Rugwani H; Vemula VK; Gora BA; Shaik S; Sharma M; Sasikala M; Padaki NR; Rajender Reddy K; Reddy DN
    Vaccine; 2022 Nov; 40(48):6971-6978. PubMed ID: 36374707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial.
    Nafar M; Mostafaloo N; Firouzan A; Poorrezagholi F; Samadian F; Dalili N; Barati S; Anjidani N; Kafi H; Shahpari R; Bayat M; Kianipour S; Samavat S
    Clin Ther; 2022 Dec; 44(12):1566-1576. PubMed ID: 36402595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients.
    Ruether DF; Schaub GM; Duengelhoef PM; Haag F; Brehm TT; Fathi A; Wehmeyer M; Jahnke-Triankowski J; Mayer L; Hoffmann A; Fischer L; Addo MM; Lütgehetmann M; Lohse AW; Schulze Zur Wiesch J; Sterneck M
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):162-172.e9. PubMed ID: 34509643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and Adverse Effects of the 2-Dose BNT162b2 Messenger RNA Vaccine Among Liver Transplantation Recipients.
    Davidov Y; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Levy I; Levin EG; Lustig Y; Mor O; Rahav G; Ben Ari Z
    Liver Transpl; 2022 Feb; 28(2):215-223. PubMed ID: 34767690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients.
    Guarino M; Esposito I; Portella G; Cossiga V; Loperto I; Tortora R; Cennamo M; Capasso M; Terracciano D; Galeota Lanza A; Di Somma S; Picciotto FP; Morisco F;
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1534-1541.e4. PubMed ID: 35066136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.
    Liu Y; Lu J; Zhan H; Yuan W; Li X; Kang H; Li H; Chen Y; Cheng L; Sun X; Zheng H; Wang W; Dai E; Li Y
    Virol Sin; 2023 Oct; 38(5):723-734. PubMed ID: 37487943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Wu Z; Hu Y; Xu M; Chen Z; Yang W; Jiang Z; Li M; Jin H; Cui G; Chen P; Wang L; Zhao G; Ding Y; Zhao Y; Yin W
    Lancet Infect Dis; 2021 Jun; 21(6):803-812. PubMed ID: 33548194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
    Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
    Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.